Vv169

Phase 1

VVyriad, Inc.

Vv169 is one of 3 therapeutic programs targeting Multiple Myeloma, Refractory. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple Myeloma, RefractoryRecruiting

Multiple Myeloma, RefractoryPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Multiple Myeloma, Refractory

#DrugCompanyPhaseTrials

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 2

Decadron

AAspen Global Incorporated

Phase 2

1 3

Vv169

VVyriad, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Multiple Myeloma, Refractory

NCT07802717

Clinical

Trials by Indication[1]

Multiple Myeloma, Refractory1 trial

A Phase 1 Dose-escalation and Expansion Study to Evaluate Safety, Pharmacodynamics and Preliminary Efficacy of VV169 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·VVyriad, Inc.·Phase 1·NCT07802717·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vv169. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vv169. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vyriad, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: VVyriad, Inc.

Vv169

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Multiple Myeloma, Refractory1 trial

References

Drug Info

Quick Facts

Related News